161 related articles for article (PubMed ID: 31179271)
1. Discovery of Coumarin as Microtubule Affinity-Regulating Kinase 4 Inhibitor That Sensitize Hepatocellular Carcinoma to Paclitaxel.
Shen X; Liu X; Wan S; Fan X; He H; Wei R; Pu W; Peng Y; Wang C
Front Chem; 2019; 7():366. PubMed ID: 31179271
[TBL] [Abstract][Full Text] [Related]
2. Vanillin-Isatin Hybrid-Induced MARK4 Inhibition As a Promising Therapeutic Strategy against Hepatocellular Carcinoma.
Ahmed S; Queen A; Irfan I; Siddiqui MN; Abdulhameed Almuqdadi HT; Setia N; Ansari J; Hussain A; Hassan MI; Abid M
ACS Omega; 2024 Jun; 9(24):25945-25959. PubMed ID: 38911744
[TBL] [Abstract][Full Text] [Related]
3. A Network-Guided Approach to Discover Phytochemical-Based Anticancer Therapy: Targeting MARK4 for Hepatocellular Carcinoma.
Ahmed S; Mobashir M; Al-Keridis LA; Alshammari N; Adnan M; Abid M; Hassan MI
Front Oncol; 2022; 12():914032. PubMed ID: 35936719
[TBL] [Abstract][Full Text] [Related]
4. Identification and evaluation of bioactive natural products as potential inhibitors of human microtubule affinity-regulating kinase 4 (MARK4).
Mohammad T; Khan FI; Lobb KA; Islam A; Ahmad F; Hassan MI
J Biomol Struct Dyn; 2019 Apr; 37(7):1813-1829. PubMed ID: 29683402
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of human microtubule affinity-regulating kinase 4 inhibitors: fluorescence binding studies, enzyme, and cell assays.
Naz F; Sami N; Naqvi AT; Islam A; Ahmad F; Imtaiyaz Hassan M
J Biomol Struct Dyn; 2017 Nov; 35(14):3194-3203. PubMed ID: 27748164
[TBL] [Abstract][Full Text] [Related]
6. PKR-inhibitor binds efficiently with human microtubule affinity-regulating kinase 4.
Naz F; Shahbaaz M; Khan S; Bisetty K; Islam A; Ahmad F; Hassan MI
J Mol Graph Model; 2015 Nov; 62():245-252. PubMed ID: 26519933
[TBL] [Abstract][Full Text] [Related]
7. Designing New Kinase Inhibitor Derivatives as Therapeutics Against Common Complex Diseases: Structural Basis of Microtubule Affinity-Regulating Kinase 4 (MARK4) Inhibition.
Naz F; Shahbaaz M; Bisetty K; Islam A; Ahmad F; Hassan MI
OMICS; 2015 Nov; 19(11):700-11. PubMed ID: 26565604
[TBL] [Abstract][Full Text] [Related]
8. Targeting inhibition of microtubule affinity regulating kinase 4 by Harmaline: Strategy to combat Alzheimer's disease.
Adnan M; Anwar S; DasGupta D; Patel M; Elasbali AM; Alhassan HH; Shafie A; Siddiqui AJ; Bardakci F; Snoussi M; Hassan MI
Int J Biol Macromol; 2023 Jan; 224():188-195. PubMed ID: 36257368
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, molecular docking and inhibition studies of novel 3-N-aryl substituted-2-heteroarylchromones targeting microtubule affinity regulating kinase 4 inhibitors.
Parveen I; Khan P; Ali S; Hassan MI; Ahmed N
Eur J Med Chem; 2018 Nov; 159():166-177. PubMed ID: 30290280
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 4-(2-(dimethylamino)ethoxy)benzohydrazide derivatives as prospective microtubule affinity regulating kinase 4 inhibitors.
Khan NS; Khan P; Inam A; Ahmad K; Yousuf M; Islam A; Ali S; Azam A; Husain M; Hassan MI
RSC Adv; 2020 May; 10(34):20129-20137. PubMed ID: 35520423
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, Structural Modification, and Bioactivity Evaluation of Substituted Acridones as Potent Microtubule Affinity-Regulating Kinase 4 Inhibitors.
Voura M; Anwar S; Sigala I; Parasidou E; Fragoulidou S; Hassan MI; Sarli V
ACS Pharmacol Transl Sci; 2023 Jul; 6(7):1052-1074. PubMed ID: 37470016
[TBL] [Abstract][Full Text] [Related]
12. Design and Development of Small-Molecule Arylaldoxime/5-Nitroimidazole Hybrids as Potent Inhibitors of MARK4: A Promising Approach for Target-Based Cancer Therapy.
Peerzada MN; Khan P; Khan NS; Avecilla F; Siddiqui SM; Hassan MI; Azam A
ACS Omega; 2020 Sep; 5(36):22759-22771. PubMed ID: 32954123
[TBL] [Abstract][Full Text] [Related]
13. Probing the Inhibition of Microtubule Affinity Regulating Kinase 4 by N-Substituted Acridones.
Voura M; Khan P; Thysiadis S; Katsamakas S; Queen A; Hasan GM; Ali S; Sarli V; Hassan MI
Sci Rep; 2019 Feb; 9(1):1676. PubMed ID: 30737440
[TBL] [Abstract][Full Text] [Related]
14. Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma.
Zhou Q; Ching AK; Leung WK; Szeto CY; Ho SM; Chan PK; Yuan YF; Lai PB; Yeo W; Wong N
Int J Oncol; 2011 Mar; 38(3):721-31. PubMed ID: 21240457
[TBL] [Abstract][Full Text] [Related]
15. PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression
Li F; Liu Z; Sun H; Li C; Wang W; Ye L; Yan C; Tian J; Wang H
Acta Pharm Sin B; 2020 Feb; 10(2):289-300. PubMed ID: 32082974
[TBL] [Abstract][Full Text] [Related]
16. Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo.
You N; Liu W; Wang T; Ji R; Wang X; Gong Z; Dou K; Tao K
Oncol Rep; 2012 Dec; 28(6):2091-100. PubMed ID: 22993037
[TBL] [Abstract][Full Text] [Related]
17. Elucidation of Dietary Polyphenolics as Potential Inhibitor of Microtubule Affinity Regulating Kinase 4: In silico and In vitro Studies.
Khan P; Rahman S; Queen A; Manzoor S; Naz F; Hasan GM; Luqman S; Kim J; Islam A; Ahmad F; Hassan MI
Sci Rep; 2017 Aug; 7(1):9470. PubMed ID: 28842631
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of microtubule affinity-regulating kinase 4 in cancer and neurodegenerative diseases.
Alam M; Ahmed S; Abid M; Hasan GM; Islam A; Hassan MI
J Cell Biochem; 2023 Sep; 124(9):1223-1240. PubMed ID: 37661636
[TBL] [Abstract][Full Text] [Related]
19. Myricetin inhibits breast and lung cancer cells proliferation via inhibiting MARK4.
Anwar S; Khan S; Anjum F; Shamsi A; Khan P; Fatima H; Shafie A; Islam A; Hassan MI
J Cell Biochem; 2022 Feb; 123(2):359-374. PubMed ID: 34751461
[TBL] [Abstract][Full Text] [Related]
20. Human microtubule affinity-regulating kinase 4 is stable at extremes of pH.
Naz F; Singh P; Islam A; Ahmad F; Imtaiyaz Hassan M
J Biomol Struct Dyn; 2016 Jun; 34(6):1241-51. PubMed ID: 26208600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
